Propionylmaridomycinの気道感染症に対する効果

DOI Web Site PubMed

書誌事項

タイトル別名
  • The Clinical Effect of Propionylmaridomycin in Respiratory Infectious Diseases
  • Propionylmaridomycinの気道感染症に対する効果 二重盲検試験
  • Propionylmaridomycin ノ キドウ カンセンショウ ニ タイスル コウカ ニジュウ モウケンシケン
  • A Study by Double Blind Method
  • 二重盲検試験

この論文をさがす

説明

Propionylmaridomycin (PMDM) is a new macrolide-series antibiotic developed by the Research Laboratories of the Takeda Chemical Ind. Ltd., in 1972. Pharmacological and bacteriological studies have shown this agent to have an antibacterial activity almost equal to that of kitasamycin (LM) both in vitro and in vivo.<BR>The study was carried out in order to compare the clinical effect of PMDM, by double blind method, in respiratory infectious diseases (bacterial pneumoniae, acute bacterial bronchitis, acute tonsillitis) with that of LM as the control; 29 patients with bacterial pneumoniae were treated by 1600mg of PMDM or LM daily for 2 weeks; 38 patients with acute bacterial bronchitis and 32 patients with acute tonsillitis were treated by daily dose of 1200mg of PMDM or LM for 1 week.<BR>The following results were obtained.<BR>1) Improvement of main symptomes of bacterial pneumoniae was observed in 11 of 16 patients treated with PMDM (68.8%) and in 9 of 13 patients treated with LM (69.2%).<BR>Improvement of main symptoms of acute bacterial bronchitis was observed in 14 of 22 patients in PMDM group (63.6%) and in 11 of 16 patients in LM group (68.8%).<BR>Improvement of main symptomes of acute tonsillitis was observed in 9 of 14 patients in PMDM group (64.3%) and in 15 of 18 patients in LM group (88.9%). The clinical effect of both antibiotics showed no significant difference.<BR>2) Gastrointestinal disturbance was main side effect and no severe side effects, such as fever, skin rash, anaemia, toxic hepatits were observed in both PMDM group and LM group.

収録刊行物

  • 感染症学雑誌

    感染症学雑誌 48 (9), 357-368, 1974

    一般社団法人 日本感染症学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ